• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4), Truncated

ACP03865

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP03865 Target NameCEACAM4
Target SynonymsCEACAM4; CGM7Carcinoembryonic antigen-related cell adhesion molecule 4; Carcinoembryonic antigen CGM7; Non-specific cross-reacting antigen W236FormLiquid or Lyophilized powder
Expression SystemYeastExpression Range36-155aa
Mol Weight14.7kDaProtein LengthPartial
PurityGreater than 90% as determined by SDS-PAGE.Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDO75871
Background Information
  • Uniprot Id

    O75871

  • Target Species

    Human

  • Target Name

    CEACAM4

  • Target Full Name

    Cell adhesion molecule CEACAM4

  • Target Function

    Granulocyte orphan receptor that acts as an trigger efficient phagocytosis of attached particles.

  • Target Subcellular Location

    Membrane; Single-pass type I membrane protein.

  • Target Protein Families

    Immunoglobulin superfamily, CEA family

  • Target Tissue Specificity

    Granulocytes.

  • Target Research Area

    Immunology

  • Target Synonyms

    CEACAM4; CGM7Carcinoembryonic antigen-related cell adhesion molecule 4; Carcinoembryonic antigen CGM7; Non-specific cross-reacting antigen W236

  • Target Background

    Involved in phagocytosis. Predicted to be located in extracellular region.

Inquire Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification